You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天康生物(002100.SZ):布氏菌病活疫苗(A19-ΔVirB12株)獲新獸藥註冊證書
格隆匯 07-22 19:27

格隆匯 7 月 22日丨天康生物(002100.SZ)公佈,根據《獸藥管理條例》和《獸藥註冊辦法》等有關規定,經中華人民共和國農業農村部審查,准予公司與其他單位聯合申報的“布氏菌病活疫苗(A19-ΔVirB12株)”為新獸藥,核發《新獸藥註冊證書》。

布氏菌病活疫苗(A19-ΔVirB12株)是以布氏桿菌病活疫苗株(A19株)為親本株,應用基因同源重組方法,缺失其毒力基因VirB12基因,獲得的布氏菌基因缺失活疫苗。動物接種該疫苗後不僅可以獲得免疫保護,而且還能將疫苗免疫動物和自然感染動物進行區別,有利於臨牀患病動物的檢疫和淘汰,從而保護人們的健康和安全。

與市場上使用的同類布病疫苗相比,該疫苗具有以下優勢:帶有基因標記,該疫苗接種動物後可區分疫苗免疫動物和自然感染動物;缺失了毒力基因,疫苗安全性更高;抗原含量精準能產生更好的免疫保護。

此次新獸藥證書的取得,將進一步豐富公司疫苗產品結構,形成多系列疫苗產品線,從而滿足用户對各類疫病的防疫需求,對持續提升公司業績產生積極的影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account